1. Gimsing P, Bjerrum OW, Brandt E, Ellegaard J, Evensen SA, Hansen MM, Hedenus M, Hippe E, Keldsen N, Palva I. Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. The Nordic Myeloma Study Group (NMSG) [see comments]. Br J Haematol 1991; 77(1):73-79.

2. Wisloff F, Gimsing P, Hedenus M, Hippe E, Palva I, Talstad I, Turesson I, Westin J. Bolus therapy with mitoxantrone and vincristine in combination with high-dose prednisone (NOP-bolus) in resistant multiple myeloma. Nordic Myeloma Study Group (NMSG). Eur J Haematol 1992; 48(2):70-74.

3. Keldsen N, Bjerrum OW, Dahl IM, Drivsholm A, Ellegaard J, Gadeberg O, Gimsing P, Gronvold T, Hansen MM, Hippe E. Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase III study. Nordic Myeloma Study Group (NMSG). Eur J Haematol 1993; 51(2):80-85.

4. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 1994; 53(4):207-212.

5. Hjorth M, Holmberg E, Rodjer S, Taube A, Westin J. Patient accrual and quality of participation in a multicentre study on myeloma: a comparison between major and minor participating centres. Br J Haematol 1995; 91(1):109-115.

6. Hjorth M. Clinical trials in multiple myeloma. Treatment results and methodological aspects [Thesis]. Göteborg University, 1995.

7. Johnsen HE. Report from a Nordic workshop on CD34+ cell analysis: technical recommandations for progenitor cell enumeration in leukapheresis from multiple myeloma patients. Nordic Myeloma Study Group Laboratories. J Hematother 1995; 4(1):21-28.

8. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group Ann Intern Med 1996; 124(2):212-222.

9. Hjorth M, Holmberg E, Rodjer S, Taube A, Westin J. Physicians' attitudes toward clinical trials and their relationship to patient accrual in a Nordic multicenter study on myeloma. Control Clin Trials 1996; 17(5):372-386.

10. Johnsen HE, Knudsen LM. Nordic flow cytometry standards for CD34+ cell enumeration in blood and leukapheresis products: report from the second Nordic Workshop. Nordic Stem Cell Laboratory Group (NSCL-G). J Hematother 1996; 5(3):237-245.

11. Wisloff F, Hjorth M, Kaasa S, Westin J. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group. Br J Haematol 1996; 94(2):324-332.

12. Wisloff F, Eika S, Hippe E, Hjorth M, Holmberg E, Kaasa S, Palva I, Westin J. Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol 1996; 92(3):604-613.

13. Abildgaard N, Bentzen SM, Nielsen JL, Heickendorff L. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG). Br J Haematol 1997; 96(1):103-110.

14. Nord E, Wisloff F, Hjorth M, Westin J. Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial. Pharmacoeconomics 1997; 12(1):89-103.

15. Wisloff F, Hjorth M. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol 1997; 97(1):29-37.

16. Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A, Waage A. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 1998; 91(3):806-812.

17. Dahl IM, Turesson I, Holmberg E, Lilja K. Serum hyaluronan in patients with multiple myeloma: correlation with survival and Ig concentration. Blood 1999; 93(12):4144-4148.

18. Hjorth M, Holmberg E, Rodjer S, Turesson I, Westin J, Wisloff F. Survival in conventionally treated younger (under 60 years) multiple myeloma patients: no improvement during two decades. Nordic Myeloma Study Group (NMSG). Eur J Haematol 1999; 62(4):271-277

19. Johnsen HE, Baech J, Nikolajsen K. Validation of the Nordic flow cytometry standard for CD34+ cell enumeration in blood and autografts: report from the third workshop. Nordic Stem Cell Laboratory Group. J Hematother 1999; 8(1):15-28.

20. Turesson I, Abildgaard N, Ahlgren T, Dahl I, Holmberg E, Hjorth M, Nielsen JL, Oden A, Seidel C, Waage A, Westin J, Wisloff F. Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors. Br J Haematol 1999; 106(4):1005-1012.

21. Wisloff F, Gulbrandsen N, Nord E. Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations. Pharmacoeconomics 1999; 16(4):329-341.

22. Hjorth M, Lenhoff S, Turesson I, Westin J. [High-dose melphalan with stem cell support is now an established myeloma therapy. Treatment of myeloma from a 30-year perspective]. Lakartidningen 2000; 97(41):4585-4592.

23. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65(3):175-181.

24. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, Wisloff F, Brinch L, Carlson K, Carlsson M, Dahl IM, Gimsing P, Hippe E, Johnsen H, Lamvik J, Lofvenberg E, Nesthus I, Rodjer S. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000; 95(1):7-11.

25. Rodjer S, Nilsson B, Westin J. Do anthracyclines have a role in the therapy of multiple myeloma? Hematol J 2000; 1(6):422-426.

26. Seidel C, Borset M, Hjertner O, Cao D, Abildgaard N, Hjorth-Hansen H, Sanderson RD, Waage A, Sundan A. High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood 2000; 96(9):3139-3146.

27. Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, Abildgaard N, Waage A, Borset M. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 2000; 95(2):388-392.

28. Wisloff F, Gulbrandsen N. Health-related quality of life and patients' perceptions in interferon-treated multiple myeloma patients. Nordic Myeloma Study Group. Acta Oncol 2000; 39(7):809-813.

29. Gulbrandsen N, Wisloff F, Brinch L, Carlson K, Dahl IM, Gimsing P, Hippe E, Hjorth M, Knudsen LM, Lamvik J, Lenhoff S, Lofvenberg E, Nesthus I, Nielsen JL, Turesson I, Westin J. Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol 2001; 18(1):65-77.

30. Gulbrandsen N, Wisloff F, Nord E, Lenhoff S, Hjorth M, Westin J. Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma. Eur J Haematol 2001; 66(5):328-336.

31. Seidel C, Hjertner O, Abildgaard N, Heickendorff L, Hjorth M, Westin J, Nielsen JL, Hjorth-Hansen H, Waage A, Sundan A, Borset M. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001; 98(7):2269-2271

32. Seidel C, Lenhoff S, Brabrand S, Anderson G, Standal T, Lanng-Nielsen J, Turesson I, Borset M, Waage A, For the Nordic Myeloma Study Group: Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy. Br J Haematol 2002; 119: 672-676.

33. Standal T, Borset M, Lenhoff S, Wisloff F, Stordal B, Sundan A, Waage A, Seidel C. Serum insulin-like growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood 2002; 100: 3925-3929.

34. Erikson T, Høglund P, Turesson I, Waage A, don BR, Wu J, Kaysen GA. Pharmacokinetics of thalidomide during dialysis and in patients with impaired renal function. J Pharm Pharmacol 2003; 55: 1701-06.

35. Abildgaard N, Brixen K, Kristensen JE, Eriksen EF, Nielsen JL, Heickendorff L. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of bone disease during standard chemotherapy. Br J Haematol 2003; 120: 235-242.

36. Brenne AT, Romstad LH, Gimsing P, Juliusson G, Turesson I, Romundstad P, Borset M, Sudan A, Waage A. A low serum level of soluble tumour necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma. Haematologica 2004; 89:552-557.

37. Standahl T, Hjorth-Hansen H, Rasmussen T, Dahl IM, Lenhoff S, Brenne AT, Seidel C, Baykov V, Waage A, Börset M, Sundan A, Hjertner Ö: Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. Haematologica 2004; 89:174-182.

38. Waage A, Turesson I, Juliusson G, Gimsing P, Gulbrandsen N, Wislöff F, Eriksson T, Westin J, Lenhoff S, Lanng Nielsen J, Hjorth M, for the Nordic Myeloma Study Group: Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. Br J Haematol 2004; 125: 149-155.

39. Gulbrandsen N, Hjermstad M, Wisløff F for the Nordic Myeloma Study Group: Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical impertance of score differences. Eur J Haematol 2004; 72: 172-180.

40. Abildgaard N, Brixen K, Eriksen EF, Kristensen JE, Nielsen JL, Heickendorff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 2004; 89: 567-577.

41. Andersen NF, Standal T, Nielsen JL, Heickendorff L, Børset M, Sørensen FB, Abildgaard N. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol 2005; 128: 210-217.

42. Carlson K, Hjorth M, Knudsen LM for the Nordic Myeloma Study Group. Toxicity in standard melphalan-prednison therapy among myeloma patients with renal failure - a restrospective analysis and recommendations for dose adjustment. Br J Haematol 2005; 128: 631-635.

43. Hippe E, Westin J, Wisløff F. Nordic Myeloma Study Group, the first 15 years: scientific collaboration and improvement of patient care. Eur J Haematol 2005; 74: 185-93.

44. Wisløff F, Gulbrandsen N, Hjorth M, Lenhoff S, Fayers P. Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes. Eur J Haematol 2005; 75: 293-98.

45. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Brit J Haematol 2006; 132: 410-51.

46. Roer O, Hammerstrom J, Lenhoff S, Mylin AK, Knudsen LM, Rasmussen T, Johnsen HE; Nordic Myeloma Study Group: Quality assessment of autografting by probability evaluation: model estimation by clinical end-points in newly diagnosed multiple myeloma patients. Cytotherapy, 8:79-88, 2006

47. Lenhoff S, Hjorth M, Turesson I, Westin J, Gimsing P, Wisløff F, Ahlberg L, Carlson K, Christiansen I, Dahl IM, Forsberg K, Gedde-Dahl T, Hammerstrøm J, Johnsen HE, Knudsen LM, Linder O, Mellqvist UH, Nesthus I, Nielsen JL. Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results with focus on the effect of response degree on survival and relapse pattern after transplantation. Haematologica 2006; 91: 1228-33.

48. Lenhoff S, Hjorth M, Westin J, Brinch L, Backström B, Carlson K, Christiansen I, Dahl IM, Gimsing P, Hammerstrøm J, Johnsen HE, Juliusson G, Linder O, Mellqvist UH, Nesthus I, Nielsen JL, Tangen JM, Turesson I. Impact of age on survival after intensive chemotherapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol 2006; 133: 389-96

49. Mylin AK, Rasmussen T, Johansen JS, Knudsen LM, Nørgaard PH, Lenhoff S, Dahl IM, Johnsen HE for the Nordic Myeloma Study Group. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells. Eur J Haematol 2006; 77: 416-24

50. Wisløff F, Kvam AK, Hjorth M, Lenhoff S. Serum calcium is an independent predictor of quality of life in multiple myeloma. Eur J Haematol 2007; 78: 29-34

51. Vangsted A, Gimsing P, Klausen TW, Andersen Nexø B, Wallin H, Andersen P, Hokland P, Lillevang ST, Vogel U. Polymorphisms in the genes ERCC2, XRCC3, and CD3EAP, influence treatment ourcome in multiple myeloma undergoing autologous bone marrow transplantation. Int J Cancer 2007; 120: 1036-45

52. Mellqvist UH, Lenhoff S, Johnsen HE, Hjorth M, Holmberg E, Juliusson G, Tangen JM, Westin J; Nordic Myeloma Study Group. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone. Cancer 2008; 112: 129-35

53. Johnsen, HE, Knudsen LM, Mylin AK, Gimsing P, Gregersen H, Abildgaard N, Andersen NF, Plesner T, Vangsted A, Mourits-Andersen T on behalf of the Nordic Myeloma Study Group. Up-front fludarabine impairs stem cell harvest in multiple myeloma: report of the NMSG 13/03 randomized placebo controlled phase II trial. Hemtology Reviews In press.

54. Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Björkstrand B, Carlson K, Dahl IM, Forsberg K, Gulbrandsen N, Haukås E, Hjertner Ø, Hjorth M, Karlsson T, Knudsen LM, Nielsen JL, Linder O, Mellqvist UH, Nesthus I, Rolke J, Strandberg M, Sørbø JH, Wisløff F, Juliusson G, Turesson I for the Nordic Myeloma Study Group. Melphalan and prednison plus thalidomid or placebo in elderly patients with multiple myeloma. Blood. In press.

55. Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, Mylin A, Gluud C, Juliusson G, Gregersen H, Hansen HH, Nesthus I, Dahl IM, Westin J, Nielsen JL, Knudsen LM, Ahlberg L, Hjorth M, Abildgaard N, Andersen NF, Linder O, Wisløff F. Heatlh-related quality of life and skeletal morbidity in patients with newly diagnosed multiple myeloma given monthly infusions of 30 mg versus 90 mg pamidronate: results of a randomised blinded Nordic Myeloma Study Group (NMSG) trial. Lancet. Accepted April 2010.